OA 中文

Company Profile

Chengdu Olymvax Biopharmaceuticals Inc.

Founded in 2009, Olymvax Biopharmaceuticals Inc. is a High-tech enterprise, focusing on the R&D, production and marketing of human-use vaccine. Its registered capital is 205.68 million CNY. The factory covers an area of 5.4 acres, with 77,000 m2 (828,800 square feet) in the construction plan and 39,000 m2 already finished. Up to the end of December, 2017, the company had 203 staffs, among which, 10 have master's degree or above, accounting for 4.92% of the associates; 16 work in R&D, taking 7.88% of the associates.



Adhering to the business philosophy of "strengthening process management, committing to continuous improvement and pursuing the highest quality", the company aims to being the “internationally well-known and domestically leading” vaccine supplier. As for the construction and management of the production workshop, besides conforming to Chinese GMP 2010, the company also referring to the standard construction and management of developed countries in Euro-America, well preparing the products’ getting into international market. As for the R&D, the company holds the bi-wheel strategy of “researching novel vaccine, upgrading traditional vaccine”. Through years’ hard working, Olymvax has formed a stair-like product development type, that is, with a rich products’ follow-up reservation, the first traditional vaccine product is about to launch into the market; several innovative vaccine and upgrading vaccine are in the process of good improvement.

Board Chairman Address

No matter what twists and turns and no matter what difficulties and obstacles are in the way of an enterprise’s coming into being and developing, as long as there is stably faith and consolidated goal, the enterprise will grow better and better and finally be a success.

Since its founding, Olymvax always keep to its original development orientation, taking scientific research and its related achievements’ transformation as its duty; taking “product benefits human” and “being the leading enterprise in the industry” as its business goal. Olymvax has formed a development mode that backboned by the outstanding and independent R&D ability, solid accumulation of technological innovation, farsighted product configuration and strict quality assurance system.

In the coming future, shouldering the holy mission of providing human beings with vaccines that are safer, better and more effective; holding the faith of “honesty, dedication, innovation and transcendence”; adopting the world’s leading technique and management, Olymvax will never stop innovation and transcendence; Olymvax will strive its best to be an internationally well-known, domestically leading supplier of vaccines.

Olymvax strives to provide the development platform for each employee, to give a stable return on investment to each investor, to make professional contributions to the social progress and technical development. I believe that with the help and support of whole Olymvax staff and cooperative partners, our goal will finally be achieved.

Management Team

Olymvax management team consists of professional personnel who have years’ experience in bio-pharmaceutical business and those have backgrounds of security, finance, marketing and overseas working or study experience. They have an average working experience  over 20 years. The management team has both good responsibility assigning and good team work spirits. Thus, the efficient running and high speed development of Olymvax’s businesses can be ensured.

  • Board of Directors
  • Supervisory Board
  • Senior Management Personnel
Event Chronicle
  • <
    Nov. 2017

    Haemophilus influenzae type b conjugate vaccine launched;

    Meningococcal group A and C polysaccharide conjugate vaccine registration for production;

    China's first super-bacteria vaccine completed the Phase I clinical study.

    Aug. 2017

    Olymvax once again identified as national high-tech enterprises

    Jul. 2017

    Haemophilus influenzae Type b Conjugate Vaccine got GMP certificate

    Jun. 2017

    Olymvax's first profuct, "Tetanus Vaccine, Absorbed" was launched on the market.

    May 2017

    Olymvax independently developed product Haemophilus influenzaetype b conjugate vaccine was issued  "Drug Registration License"

    Since its listing in the stock market, Olymvax got the third financing of 60 million CNY and brought its registered capital increased to 205.68 million CNY.

    Mar. 2017

    Olymvax was honored High-tech Zone "2016 Annual Intelligent Manufacturing Standard Enterprise"

  • <
    Jan. 2017

    Meningococcal Group A Group C Meningococcal-Haemophilus influenzae type b (Conjugate) Combination Vaccine got clinical approva

    Dec. 2016

    Olymvax was issued GMP Certificate for Tetanus Vaccine, Absorbed.

    Oct. 2016

    Olymvax's first profuct, "Tetanus Vaccine, Absorbed" was issued the Drug Registration License.

    Jul. 2016

    Officially the Co-development of Class 1 New Drug, Group A Streptococcus Vaccine, between Olymvax and Australian Griffith University was initiated.

    Feb. 2016

    Since its listing in the stock market, Olymvax got its first financing and brought in 2 market makers, its registered capital increased to 189.02 million CNY.

    Dec. 2015

    Olymvax received its renewed Drug Manufacturing License.

  • <
    Jun. 2015

    Olymvax merged Chongqing Yuanlun Biopharmaceutical Technological Co., Ltd.

    Jun. 2015

    Recombinant Staphylococcus Aureus Vaccine (E. Coli.), Class I novel drug, co-developed with the Third Military Medical University, was issued Drug Clinical Trial Approval File.

    Sep. 2015

    Olymvax was Officially listed in China National Equities Exchange and Quotations Market, the stock coded 833577 is shortly named as “Olymvax Biopharmaceuticals”.

    Apr. 2015

    Olymvax finished its third financing, and the registered capital increased to 158million CNY.

    Oct. 2014

    Olymvax was honored as National Hi-Tech Enterprise.

    Jul. 2013

    Olymvax finalized its second financing, and the registered capital increased to 138 million CNY.

  • <
    Apr. 2013

    Haemophilus Influenzae Type b Conjugate Vaccine, developed by Olymvax was issued Drug Clinical Trial Approval File.

    Oct. 2012

    The vaccine production base-Stage I project of Olymvax was completed and put into use.

    Absorbed Tetanus Vaccine, developed by Olymvax was issued Drug Clinical Trial Approval File.

    Feb. 2012

    Olymvax finalized its first financing, and the registered capital increased to 100million CNY.

    Jul. 2011

    Olymvax was issued the Drug Manufacturing License for the first time.

    May. 2010

    Vaccine R&D laboratory was completed and put into use.

    Dec. 2009

    Chengdu Olymvax Biopharmaceuticals Inc. was founded and its registered capital was 50 million CNY.

Organization Structure


Qualification Honor